Cargando…

Use of guideline-recommended drug therapy in patients undergoing percutaneous coronary intervention for stable coronary heart disease in Germany: a multilevel analysis of nationwide routine data

OBJECTIVES: To determine the prescription of guideline recommended drug therapy in patients with stable coronary heart disease (sCHD) prior to percutaneous coronary intervention (PCI) in Germany and to examine the role of patient characteristics and features of regional healthcare supply in a multil...

Descripción completa

Detalles Bibliográficos
Autores principales: Frank-Tewaag, Julia, Bleek, Julian, Horenkamp-Sonntag, Dirk, Marschall, Ursula, Zeymer, Uwe, Donner-Banzhoff, Norbert, Sundmacher, Leonie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737102/
https://www.ncbi.nlm.nih.gov/pubmed/33318120
http://dx.doi.org/10.1136/bmjopen-2020-042886
_version_ 1783622886535200768
author Frank-Tewaag, Julia
Bleek, Julian
Horenkamp-Sonntag, Dirk
Marschall, Ursula
Zeymer, Uwe
Donner-Banzhoff, Norbert
Sundmacher, Leonie
author_facet Frank-Tewaag, Julia
Bleek, Julian
Horenkamp-Sonntag, Dirk
Marschall, Ursula
Zeymer, Uwe
Donner-Banzhoff, Norbert
Sundmacher, Leonie
author_sort Frank-Tewaag, Julia
collection PubMed
description OBJECTIVES: To determine the prescription of guideline recommended drug therapy in patients with stable coronary heart disease (sCHD) prior to percutaneous coronary intervention (PCI) in Germany and to examine the role of patient characteristics and features of regional healthcare supply in a multilevel model. DESIGN: Secondary data analysis of factors associated with the prescription of guideline recommended drug therapy using a multilevel model to analyse regional-level effects, over and above the effects of patient-level demographic and health status. SETTING: Office-based prescriptions in the year prior to the invasive procedure. PARTICIPANTS: A linked nationwide dataset from Germany’s three largest statutory health insurance funds of all patients receiving PCI in the year 2016. MAIN OUTCOME MEASURES: Patients’ odds of receiving optimal medical therapy and symptom-oriented therapy within 1 year prior to PCI. RESULTS: 68.6% of patients received at least one lipid-lowering drug and one symptom-oriented therapy prior to PCI. 43.6% received at least two agents to control their symptoms. Patients who received treatment in accordance with the recommendations had a greater number of diagnosed risk factors, a more severe history of cardiac disease and used a higher volume of ambulatory office-based physician services. The prescriptions prevalence for the symptom-oriented therapies differed significantly between eastern and western Germany, with a higher prevalence in the eastern districts. CONCLUSIONS: Guidelines can only provide decision-making corridors, and the applicability of recommendations must always be assessed on a case by case basis. Nevertheless, our analysis indicates that the prevalence of prescriptions in routine practice is subject to substantial variation and that conservative therapy options are not fully exhausted prior to PCI. This suggests that there might be room for improvement in the care of patients with sCHD.
format Online
Article
Text
id pubmed-7737102
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-77371022020-12-28 Use of guideline-recommended drug therapy in patients undergoing percutaneous coronary intervention for stable coronary heart disease in Germany: a multilevel analysis of nationwide routine data Frank-Tewaag, Julia Bleek, Julian Horenkamp-Sonntag, Dirk Marschall, Ursula Zeymer, Uwe Donner-Banzhoff, Norbert Sundmacher, Leonie BMJ Open Health Services Research OBJECTIVES: To determine the prescription of guideline recommended drug therapy in patients with stable coronary heart disease (sCHD) prior to percutaneous coronary intervention (PCI) in Germany and to examine the role of patient characteristics and features of regional healthcare supply in a multilevel model. DESIGN: Secondary data analysis of factors associated with the prescription of guideline recommended drug therapy using a multilevel model to analyse regional-level effects, over and above the effects of patient-level demographic and health status. SETTING: Office-based prescriptions in the year prior to the invasive procedure. PARTICIPANTS: A linked nationwide dataset from Germany’s three largest statutory health insurance funds of all patients receiving PCI in the year 2016. MAIN OUTCOME MEASURES: Patients’ odds of receiving optimal medical therapy and symptom-oriented therapy within 1 year prior to PCI. RESULTS: 68.6% of patients received at least one lipid-lowering drug and one symptom-oriented therapy prior to PCI. 43.6% received at least two agents to control their symptoms. Patients who received treatment in accordance with the recommendations had a greater number of diagnosed risk factors, a more severe history of cardiac disease and used a higher volume of ambulatory office-based physician services. The prescriptions prevalence for the symptom-oriented therapies differed significantly between eastern and western Germany, with a higher prevalence in the eastern districts. CONCLUSIONS: Guidelines can only provide decision-making corridors, and the applicability of recommendations must always be assessed on a case by case basis. Nevertheless, our analysis indicates that the prevalence of prescriptions in routine practice is subject to substantial variation and that conservative therapy options are not fully exhausted prior to PCI. This suggests that there might be room for improvement in the care of patients with sCHD. BMJ Publishing Group 2020-12-13 /pmc/articles/PMC7737102/ /pubmed/33318120 http://dx.doi.org/10.1136/bmjopen-2020-042886 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Health Services Research
Frank-Tewaag, Julia
Bleek, Julian
Horenkamp-Sonntag, Dirk
Marschall, Ursula
Zeymer, Uwe
Donner-Banzhoff, Norbert
Sundmacher, Leonie
Use of guideline-recommended drug therapy in patients undergoing percutaneous coronary intervention for stable coronary heart disease in Germany: a multilevel analysis of nationwide routine data
title Use of guideline-recommended drug therapy in patients undergoing percutaneous coronary intervention for stable coronary heart disease in Germany: a multilevel analysis of nationwide routine data
title_full Use of guideline-recommended drug therapy in patients undergoing percutaneous coronary intervention for stable coronary heart disease in Germany: a multilevel analysis of nationwide routine data
title_fullStr Use of guideline-recommended drug therapy in patients undergoing percutaneous coronary intervention for stable coronary heart disease in Germany: a multilevel analysis of nationwide routine data
title_full_unstemmed Use of guideline-recommended drug therapy in patients undergoing percutaneous coronary intervention for stable coronary heart disease in Germany: a multilevel analysis of nationwide routine data
title_short Use of guideline-recommended drug therapy in patients undergoing percutaneous coronary intervention for stable coronary heart disease in Germany: a multilevel analysis of nationwide routine data
title_sort use of guideline-recommended drug therapy in patients undergoing percutaneous coronary intervention for stable coronary heart disease in germany: a multilevel analysis of nationwide routine data
topic Health Services Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737102/
https://www.ncbi.nlm.nih.gov/pubmed/33318120
http://dx.doi.org/10.1136/bmjopen-2020-042886
work_keys_str_mv AT franktewaagjulia useofguidelinerecommendeddrugtherapyinpatientsundergoingpercutaneouscoronaryinterventionforstablecoronaryheartdiseaseingermanyamultilevelanalysisofnationwideroutinedata
AT bleekjulian useofguidelinerecommendeddrugtherapyinpatientsundergoingpercutaneouscoronaryinterventionforstablecoronaryheartdiseaseingermanyamultilevelanalysisofnationwideroutinedata
AT horenkampsonntagdirk useofguidelinerecommendeddrugtherapyinpatientsundergoingpercutaneouscoronaryinterventionforstablecoronaryheartdiseaseingermanyamultilevelanalysisofnationwideroutinedata
AT marschallursula useofguidelinerecommendeddrugtherapyinpatientsundergoingpercutaneouscoronaryinterventionforstablecoronaryheartdiseaseingermanyamultilevelanalysisofnationwideroutinedata
AT zeymeruwe useofguidelinerecommendeddrugtherapyinpatientsundergoingpercutaneouscoronaryinterventionforstablecoronaryheartdiseaseingermanyamultilevelanalysisofnationwideroutinedata
AT donnerbanzhoffnorbert useofguidelinerecommendeddrugtherapyinpatientsundergoingpercutaneouscoronaryinterventionforstablecoronaryheartdiseaseingermanyamultilevelanalysisofnationwideroutinedata
AT sundmacherleonie useofguidelinerecommendeddrugtherapyinpatientsundergoingpercutaneouscoronaryinterventionforstablecoronaryheartdiseaseingermanyamultilevelanalysisofnationwideroutinedata